FDA Approves First Gene Therapy for Pediatric Patients With Sanfilippo Syndrome Type A

A Rare and Progressive Genetic Disease

Sanfilippo syndrome type A is a rare inherited lysosomal storage disorder caused by mutations affecting the SGSH gene. The disease results in a deficiency of the enzyme sulfamidase, which is needed to break down heparan sulfate.

When the enzyme is deficient, heparan sulfate accumulates inside cells, including cells in the central nervous system. Over time, this buildup can contribute to progressive neurological and developmental deterioration.

Children may initially develop relatively normally before experiencing developmental delays and progressive loss of cognitive, language and other abilities. Before Fayuvi's approval, treatment options were primarily focused on managing symptoms and supportive care rather than an FDA-approved therapy designed to address the underlying cause of MPS IIIA.

How Fayuvi Works

Fayuvi is a one-time intravenous gene therapy that uses a modified, non-infectious adeno-associated virus serotype 9 (AAV9) to deliver a functional copy of the SGSH gene to cells.

The goal is for treated cells to produce functional sulfamidase. This enzyme can then help break down accumulated heparan sulfate within lysosomes, reducing the substrate that contributes to disease progression.

The use of AAV9 is particularly significant because the vector can reach the central nervous system, an important target in MPS IIIA because neurological disease is a major component of the condition.

Clinical Evidence

The FDA evaluated Fayuvi in an open-label, single-arm, multicenter clinical study involving pediatric patients with MPS IIIA.

One of the key measures was cognitive development in children between 2 and 5 years of age. According to the FDA, children treated with Fayuvi maintained or improved cognitive function compared with an untreated historical control cohort.

The clinical development program included the Transpher A study and additional long-term follow-up. FDA approval documents identify clinical trials associated with:

Long-term follow-up was an important component of the evidence supporting the approval, given the progressive nature of MPS IIIA and the need to understand whether the effects of a one-time gene therapy can persist over time.

Leading complex gene therapy administration and tracking developmental trajectories requires close oversight by pediatric geneticists, child neurologists, and specialized Physicians / MD-DO who serve as clinical investigators and manage multisystem treatment regimens.

Safety and Monitoring

As with other gene therapies, Fayuvi carries important safety considerations.

The FDA reported that commonly observed adverse reactions included:

• Increased liver enzymes, including AST
• Nausea and vomiting
• Fever
• Decreased appetite
• Decreased white blood cell and platelet counts
• Increased amylase

The FDA also notes a potential long-term risk associated with AAV-based gene therapies: genetic material delivered by the therapy could potentially integrate into the patient's genome, with a theoretical risk of contributing to tumor development. Long-term monitoring is therefore an important part of treatment and follow-up.

To manage intensive pre-infusion corticosteroid regimens, laboratory surveillance, and multi-week outpatient recovery, metabolic treatment centers rely on dedicated Nurse Practitioners (NP) who spearhead care coordination, biomarker evaluations, and family education.

Fayuvi is administered in a specialized healthcare setting capable of managing acute infusion-related reactions. During the acute delivery phase, pediatric cellular therapy units and ICU environments mobilize experienced Registered Nurses (RN) / Travel Nursing to monitor real-time hemodynamic parameters, vector infusion protocols, and emergency safety interventions.

FDA Designations and Priority Review Voucher

During development, Fayuvi received several FDA designations intended to facilitate the development and review of therapies for serious and rare diseases. These included Orphan Drug, Fast Track and Breakthrough Therapy designations.

Ultragenyx also received a Rare Pediatric Disease Priority Review Voucher (PRV) as part of the approval.

The voucher can provide priority review for a future qualifying drug or biologic application and can also be transferred under the conditions established by the FDA.

Significance for Pediatric Gene Therapy

The approval represents a significant development in the treatment of Sanfilippo syndrome type A. It also adds to the growing number of gene therapies being developed and approved for rare pediatric diseases.

For families affected by MPS IIIA, the availability of an FDA-approved therapy specifically targeting the underlying genetic cause introduces a new treatment option where previously there was no approved disease-modifying therapy.

The approval also illustrates the broader potential of gene therapy for inherited disorders in which a missing or defective protein contributes to progressive disease. By delivering a functional gene rather than repeatedly administering the missing enzyme, Fayuvi is designed as a single-dose treatment intended to provide a long-term biological effect.

At the same time, the therapy requires specialized administration, corticosteroid treatment and ongoing medical monitoring because of the potential for serious adverse events and the uncertainties associated with long-term gene therapy.

Looking Ahead

Fayuvi's approval is expected to increase access to gene therapy for children diagnosed with MPS IIIA and may also contribute to earlier treatment strategies as diagnostic capabilities develop.

Earlier diagnosis could be particularly important for progressive neurological disorders because treatment before substantial neurological damage occurs may provide a greater opportunity to preserve developmental function.

Given the rigorous requirement for multi-year neurocognitive monitoring and long-term registry tracking across geographically dispersed families, academic medical networks are expanding Telehealth / Remote / Virtual Jobs to coordinate developmental milestone checks, lab scheduling, and continuous home-based assessments.

The FDA's decision marks a new chapter in the treatment of Sanfilippo syndrome type A and demonstrates the continued expansion of gene therapy into rare pediatric neurological diseases.